The treatment of varicella-zoster virus infection and its complications

Bibliography

• Mandell GL, Douglas RG, Bennett JE, Dolin R. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. Sixth edition. Philadelphia, Pa.: Elsevier/Churchill Livingstone, 2005
   Google Scholar
• Quinlivan M, Breuer J. Molecular and therapeutic aspects of varicella-zoster virus infection. Expert Rev Mol Med 2005;7(15):1-24
   PubMedGoogle Scholar
• Reichelt M, Zerboni L, Arvin AM. Mechanisms of varicella-zoster virus neuropathogenesis in human dorsal root ganglia. J Virol 2008;82(8):3971-83
   PubMed Web of Science ®Google Scholar
• Ku CC, Besser J, Abendroth A, et al. Varicella-Zoster virus pathogenesis and immunobiology: new concepts emerging from investigations with the SCIDhu mouse model. J Virol 2005;79(5):2651-8
   PubMed Web of Science ®Google Scholar
• Nardone A, de Ory F, Carton M, et al. The comparative sero-epidemiology of varicella zoster virus in 11 countries in the European region. Vaccine 2007;25(45):7866-72
   PubMed Web of Science ®Google Scholar
• Johnson R, McElhaney J, Pedalino B, Levin M. Prevention of herpes zoster and its painful and debilitating complications. Int J Infect Dis 2007;11(Suppl 2):S43-8
   PubMed Web of Science ®Google Scholar
• Malavige GN, Jones L, Kamaladasa SD, et al. Viral load, clinical disease severity and cellular immune responses in primary varicella zoster virus infection in Sri Lanka. PLoS One 2008;3(11):e3789
   PubMed Web of Science ®Google Scholar
• Heininger U, Seward JF. Varicella. Lancet 2006;368(9544):1365-76
   PubMed Web of Science ®Google Scholar
• Meyer PA, Seward JF, Jumaan AO, Wharton M. Varicella mortality: trends before vaccine licensure in the United States, 1970-1994. J Infect Dis 2000;182(2):383-90
   PubMed Web of Science ®Google Scholar
• Harger JH, Ernest JM, Thurnau GR, et al. Risk factors and outcome of varicella-zoster virus pneumonia in pregnant women. J Infect Dis 2002;185(4):422-7
   PubMed Web of Science ®Google Scholar
• Tan MP, Koren G. Chickenpox in pregnancy: revisited. Reprod Toxicol 2006;21(4):410-20
   PubMed Web of Science ®Google Scholar
• Chickenpox, pregnancy and the newborn. Drug Ther Bull 2005;43(9):69-72
   PubMedGoogle Scholar
• Royal College of Obstetricians and Gynaecologists. Chickenpox in Pregnancy. Green-top Guideline No. 13. September 2007.
   Google Scholar
• Gershon AA, Chen J, Gershon MD. A model of lytic, latent, and reactivating varicella-zoster virus infections in isolated enteric neurons. J Infect Dis 2008;197(Suppl 2):S61-5
   Google Scholar
• Mckendrick MW, Care CC, Kudesia G, et al. Is VZV reactivation a common cause of unexplained unilateral pain? Results of a prospective study of 57 patients. J Infect 1999;39(3):209-12
   PubMedGoogle Scholar
• Levin MJ, Smith JG, Kaufhold RM, et al. Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine. J Infect Dis 2003;188(9):1336-44
   PubMed Web of Science ®Google Scholar
• Arvin A. Aging, immunity, and the varicella-zoster virus. N Engl J Med 2005;352(22):2266-7
   PubMed Web of Science ®Google Scholar
• Steiner I, Kennedy PG, Pachner AR. The neurotropic herpes viruses: herpes simplex and varicella-zoster. Lancet Neurol 2007;6(11):1015-28
   PubMed Web of Science ®Google Scholar
• Oaklander AL. Mechanisms of pain and itch caused by herpes zoster (shingles). J Pain 2008;9(1 Suppl 1):S10-8
   PubMed Web of Science ®Google Scholar
• Wasner G, Kleinert A, Binder A, et al. Postherpetic neuralgia: topical lidocaine is effective in nociceptor-deprived skin. J Neurol 2005;252(6):677-86
   PubMed Web of Science ®Google Scholar
• Fields HL, Rowbotham M, Baron R. Postherpetic neuralgia: irritable nociceptors and deafferentation. Neurobiol Dis 1998;5(4):209-27
   PubMed Web of Science ®Google Scholar
• Watson CP, Deck JH, Morshead C, et al. Post-herpetic neuralgia: further post-mortem studies of cases with and without pain. Pain 1991;44(2):105-17
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Portenoy RK. Proposed classification of herpes zoster pain. Lancet 1994;343(8913):1648
   PubMed Web of Science ®Google Scholar
• Jung BF, Johnson RW, Griffin DR, Dworkin RH. Risk factors for postherpetic neuralgia in patients with herpes zoster. Neurology 2004;62(9):1545-51
   PubMed Web of Science ®Google Scholar
• Jensen MP, Chodroff MJ, Dworkin RH. The impact of neuropathic pain on health-related quality of life: review and implications. Neurology 2007;68(15):1178-82
   PubMed Web of Science ®Google Scholar
• van Seventer R, Sadosky A, Lucero M, Dukes E. A cross-sectional survey of health state impairment and treatment patterns in patients with postherpetic neuralgia. Age Ageing 2006;35(2):132-7
   PubMed Web of Science ®Google Scholar
• Gauthier A, Breuer J, Carrington D, et al. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect 2009;137(1):38-47
   PubMed Web of Science ®Google Scholar
• Schmader K, Gnann JW Jr, Watson CP. The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine. J Infect Dis 2008;197 (Suppl 2):S207-15
   PubMed Web of Science ®Google Scholar
• Binder A, Koroschetz J, Baron R. Disease mechanisms in neuropathic itch. Nat Clin Pract Neurol 2008;4(6):329-37
   PubMedGoogle Scholar
• Oaklander AL, Cohen SP, Raju SV. Intractable postherpetic itch and cutaneous deafferentation after facial shingles. Pain 2002;96(1-2):9-12
   PubMed Web of Science ®Google Scholar
• Liesegang TJ. Herpes zoster ophthalmicus natural history, risk factors, clinical presentation, and morbidity. Ophthalmology 2008;115(2 Suppl):S3-12
   Web of Science ®Google Scholar
• Schmader KE, Dworkin RH. Natural history and treatment of herpes zoster. J Pain 2008;9(1 Suppl 1):S3-9
   PubMed Web of Science ®Google Scholar
• Ahmed AM, Brantley JS, Madkan V, et al. Managing herpes zoster in immunocompromised patients. Herpes 2007;14(2):32-6
   PubMedGoogle Scholar
• Wu CL, Raja SN. An update on the treatment of postherpetic neuralgia. J Pain 2008;9(1 Suppl 1):S19-30
   PubMed Web of Science ®Google Scholar
• Peterslund NA, Seyer-Hansen K, Ipsen J, et al. Acyclovir in herpes zoster. Lancet 1981;2(8251):827-30
   PubMed Web of Science ®Google Scholar
• De Clercq E, Field HJ. Antiviral prodrugs – the development of successful prodrug strategies for antiviral chemotherapy. Br J Pharmacol 2006;147(1):1-11
   PubMed Web of Science ®Google Scholar
• Arvin AM. Varicella-zoster virus. Clin Microbiol Rev 1996;9(3):361-81
   PubMed Web of Science ®Google Scholar
• MacDougall C, Guglielmo BJ. Pharmacokinetics of valaciclovir. J Antimicrob Chemother 2004;53(6):899-901
   PubMed Web of Science ®Google Scholar
• Beutner KR, Friedman DJ, Forszpaniak C, et al. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 1995;39(7):1546-53
   PubMed Web of Science ®Google Scholar
• Huynh TH, Johnson MW, Comer GM, Fish DN. Vitreous penetration of orally administered valacyclovir. Am J Ophthalmol 2008;145(4):682-6
   PubMed Web of Science ®Google Scholar
• Arora A, Mendoza N, Brantley J, et al. Double-blind study comparing 2 dosages of valacyclovir hydrochloride for the treatment of uncomplicated herpes zoster in immunocompromised patients 18 years of age and older. J Infect Dis 2008;197(9):1289-95
   PubMed Web of Science ®Google Scholar
• Earnshaw DL, Bacon TH, Darlison SJ, et al. Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus. Antimicrob Agents Chemother 1992;36(12):2747-57
   PubMed Web of Science ®Google Scholar
• Cirelli R, Herne K, McCrary M, et al. Famciclovir: review of clinical efficacy and safety. Antiviral Res 1996;29(2-3):141-51
   PubMed Web of Science ®Google Scholar
• Saltzman R, Jurewicz R, Boon R. Safety of famciclovir in patients with herpes zoster and genital herpes. Antimicrob Agents Chemother 1994;38(10):2454-7
   PubMed Web of Science ®Google Scholar
• Klassen TP, Hartling L, Wiebe N, Belseck EM. Acyclovir for treating varicella in otherwise healthy children and adolescents. Cochrane Database Syst Rev 2005;(4):CD002980
   Google Scholar
• Izzedine H, Launay-Vacher V, Deray G. Antiviral drug-induced nephrotoxicity. Am J Kidney Dis 2005;45(5):804-17
   PubMed Web of Science ®Google Scholar
• Carlon R, Possamai C, Corbanese U. Acute renal failure and severe neurotoxicity following valacyclovir. Intensive Care Med 2005;31(11):1593
   PubMed Web of Science ®Google Scholar
• Htwe TH, Bergman S, Koirala J. Famciclovir substitution for patients with acyclovir-associated renal toxicity. J Infect 2008;57(3):266-8
   PubMed Web of Science ®Google Scholar
• Bell WR, Chulay JD, Feinberg JE. Manifestations resembling thrombotic microangiopathy in patients with advanced human immunodeficiency virus (HIV) disease in a cytomegalovirus prophylaxis trial (ACTG 204). Medicine 1997;76(5):369-80
   PubMed Web of Science ®Google Scholar
• Hellden A, Lycke J, Vander T, et al. The aciclovir metabolite CMMG is detectable in the CSF of subjects with neuropsychiatric symptoms during aciclovir and valaciclovir treatment. J Antimicrob Chemother 2006;57(5):945-9
   PubMed Web of Science ®Google Scholar
• Mahad DJ, Hellden A, Jarvis J, et al. Aciclovir induced posterior leucoencephalopathy. J Neurol Neurosurg Psychiatry 2005;76(9):1308-9
   PubMedGoogle Scholar
• Yang HH, Hsiao YP, Shih HC, Yang JH. Acyclovir-induced neuropsychosis successfully recovered after immediate hemodialysis in an end-stage renal disease patient. Int J Dermatol 2007;46(8):883-4
   PubMed Web of Science ®Google Scholar
• De Clercq E, Descamps J, Ogata M, Shigeta S. In vitro susceptibility of varicella-zoster virus to E-5-(2-bromovinyl)-2'-deoxyuridine and related compounds. Antimicrob Agents Chemother 1982;21(1):33-8
   PubMed Web of Science ®Google Scholar
• Andrei G, Snoeck R, Reymen D, et al. Comparative activity of selected antiviral compounds against clinical isolates of varicella-zoster virus. Eur J Clin Microbiol Infect Dis 1995;14(4):318-29
   PubMed Web of Science ®Google Scholar
• Wassilew SW, Wutzler P. Oral brivudin in comparison with acyclovir for improved therapy of herpes zoster in immunocompetent patients: results of a randomized, double-blind, multicentered study. Antiviral Res 2003;59(1):49-56
   PubMed Web of Science ®Google Scholar
• Enright AM, Prober C. Antiviral therapy in children with varicella zoster virus and herpes simplex virus infections. Herpes 2003;10(2):32-7
   PubMedGoogle Scholar
• Gilbert C, Bestman-Smith J, Boivin G. Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. Drug Resist Updat 2002;5(2):88-114
   PubMed Web of Science ®Google Scholar
• Talarico CL, Phelps WC, Biron KK. Analysis of the thymidine kinase genes from acyclovir-resistant mutants of varicella-zoster virus isolated from patients with AIDS. J Virol 1993;67(2):1024-33
   PubMed Web of Science ®Google Scholar
• Visse B, Dumont B, Huraux JM, Fillet AM. Single amino acid change in DNA polymerase is associated with foscarnet resistance in a varicella-zoster virus strain recovered from a patient with AIDS. J Infect Dis 1998;178(Suppl 1):S55-7
   PubMedGoogle Scholar
• Harris D, Redhead J. Should acyclovir be prescribed for immunocompetent children presenting with chickenpox? Arch Dis Child 2005;90(6):648-50
   PubMedGoogle Scholar
• Balfour HH Jr, Edelman CK, Anderson RS, et al. Controlled trial of acyclovir for chickenpox evaluating time of initiation and duration of therapy and viral resistance. Pediatr Infect Dis J 2001;20(10):919-26
   PubMedGoogle Scholar
• Marin M, Watson TL, Chaves SS, et al. Varicella among adults: data from an active surveillance project, 1995-2005. J Infect Dis 2008;197(Suppl 2):S94-100
   PubMed Web of Science ®Google Scholar
• Wallace MR, Bowler WA, Murray NB, et al. Treatment of adult varicella with oral acyclovir. A randomized, placebo-controlled trial. Ann Intern Med 1992;117(5):358-63
   PubMed Web of Science ®Google Scholar
• Mohsen AH, Mckendrick M. Varicella pneumonia in adults. Eur Respir J 2003;21(5):886-91
   PubMedGoogle Scholar
• Prober CG, Kirk LE, Keeney RE. Acyclovir therapy of chickenpox in immunosuppressed children–a collaborative study. J Pediatr 1982;101(4):622-5
   PubMed Web of Science ®Google Scholar
• Balfour HH Jr, McMonigal KA, Bean B. Acyclovir therapy of varicella-zoster virus infections in immunocompromised patients. J Antimicrob Chemother 1983;12(Suppl B):169-79
   PubMedGoogle Scholar
• Meszner Z, Nyerges G, Bell AR. Oral acyclovir to prevent dissemination of varicella in immunocompromised children. J Infect 1993;26(1):9-15
   PubMed Web of Science ®Google Scholar
• Brown SD, White CA, Chu CK, Bartlett MG. Determination of acyclovir in maternal plasma, amniotic fluid, fetal and placental tissues by high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2002;772(2):327-34
   PubMed Web of Science ®Google Scholar
• Stone KM, Reiff-Eldridge R, White AD, et al. Pregnancy outcomes following systemic prenatal acyclovir exposure: conclusions from the international acyclovir pregnancy registry, 1984-1999. Birth Defects Res A Clin Mol Teratol 2004;70(4):201-7
   PubMed Web of Science ®Google Scholar
• Tunbridge AJ, Breuer J, Jeffery KJ. Chickenpox in adults – clinical management. J Infect 2008;57(2):95-102
   PubMed Web of Science ®Google Scholar
• Salisbury D, Ramsay M, Noakes K. Immunisation against infectious disease. Third edition. In: David Salisbury, Mary Ramsay, Karen Noakes, editors. London: TSO, 2006
   Google Scholar
• Boeckh M. Prevention of VZV infection in immunosuppressed patients using antiviral agents. Herpes 2006;13(3):60-5
   PubMedGoogle Scholar
• McKendrick MW, Lau J, Alston S, Bremner J. VZV infection in pregnancy: a retrospective review over 5 years in Sheffield and discussion on the potential utilisation of varicella vaccine in prevention. J Infect 2007;55(1):64-7
   PubMedGoogle Scholar
• Lin TY, Huang YC, Ning HC, Hsueh C. Oral acyclovir prophylaxis of varicella after intimate contact. Pediatr Infect Dis J 1997;16(12):1162-5
   PubMedGoogle Scholar
• Whitley RJ, Weiss H, Gnann JW Jr, et al. Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Ann Intern Med 1996;125(5):376-83
   PubMed Web of Science ®Google Scholar
• McKendrick MW, McGill JI, White JE, Wood MJ. Oral acyclovir in acute herpes zoster. Br Med J 1986;293(6561):1529-32
   PubMed Web of Science ®Google Scholar
• Bean B, Braun C, Balfour HH Jr. Acyclovir therapy for acute herpes zoster. Lancet 1982;2(8290):118-21
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Johnson RW, Breuer J, et al. Recommendations for the management of herpes zoster. Clin Infect Dis 2007;44(Suppl 1):S1-26
   PubMed Web of Science ®Google Scholar
• Jackson JL, Gibbons R, Meyer G, Inouye L. The effect of treating herpes zoster with oral acyclovir in preventing postherpetic neuralgia. A meta-analysis. Arch Intern Med 1997;157(8):909-12
   PubMed Web of Science ®Google Scholar
• McKendrick MW, Care CD, Ogan P, Wood MJ. A Long Term Follow-Up Study Of Patients Following Herpes Zoster Varicella-Zoster Research Foundation European meeting. Paris 1994
   Google Scholar
• Wood MJ, Johnson RW, McKendrick MW, et al. A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. N Engl J Med 1994;330(13):896-900
   PubMed Web of Science ®Google Scholar
• Wood MJ, Shukla S, Fiddian AP, Crooks RJ. Treatment of acute herpes zoster: effect of early (< 48 h) versus late (48-72 h) therapy with acyclovir and valaciclovir on prolonged pain. J Infect Dis 1998;178(Suppl 1):S81-4
   Google Scholar
• Balfour HH Jr, Bean B, Laskin OL, et al. Acyclovir halts progression of herpes zoster in immunocompromised patients. N Engl J Med 1983;308(24):1448-53
   PubMed Web of Science ®Google Scholar
• Tyring S, Barbarash RA, Nahlik JE, et al. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Collaborative Famciclovir Herpes Zoster Study Group. Ann Intern Med 1995;123(2):89-96
   PubMed Web of Science ®Google Scholar
• Shafran SD, Tyring SK, Ashton R, et al. Once, twice, or three times daily famciclovir compared with aciclovir for the oral treatment of herpes zoster in immunocompetent adults: a randomized, multicenter, double-blind clinical trial. J Clin Virol 2004;29(4):248-53
   PubMed Web of Science ®Google Scholar
• Degreef H. Famciclovir, a new oral antiherpes drug: results of the first controlled clinical study demonstrating its efficacy and safety in the treatment of uncomplicated herpes zoster in immunocompetent patients. Int J Antimicrob Agents 1994;4(4):241-6
   PubMed Web of Science ®Google Scholar
• Tyring SK, Beutner KR, Tucker BA, et al. Antiviral therapy for herpes zoster: randomized, controlled clinical trial of valacyclovir and famciclovir therapy in immunocompetent patients 50 years and older. Arch Fam Med 2000;9(9):863-9
   PubMedGoogle Scholar
• Dworkin RH, Boon RJ, Griffin DR, Phung D. Postherpetic neuralgia: impact of famciclovir, age, rash severity, and acute pain in herpes zoster patients. J Infect Dis 1998;178(Suppl 1):S76-80
   PubMed Web of Science ®Google Scholar
• Tyring S, Belanger R, Bezwoda W, et al. A randomized, double-blind trial of famciclovir versus acyclovir for the treatment of localized dermatomal herpes zoster in immunocompromised patients. Cancer Invest 2001;19(1):13-22
   PubMed Web of Science ®Google Scholar
• Wutzler P, De Clercq E, Wutke K, Farber I. Oral brivudin vs. intravenous acyclovir in the treatment of herpes zoster in immunocompromised patients: a randomized double-blind trial. J Med Virol 1995;46(3):252-7
   PubMed Web of Science ®Google Scholar
• Erard V, Guthrie KA, Varley C, et al. One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation. Blood 2007;110(8):3071-7
   PubMed Web of Science ®Google Scholar
• Gilden DH, Cohrs RJ, Hayward AR, et al. Chronic varicella-zoster virus ganglionitis–a possible cause of postherpetic neuralgia. J Neurovirol 2003;9(3):404-7
   PubMedGoogle Scholar
• Quan D, Hammack BN, Kittelson J, Gilden DH. Improvement of postherpetic neuralgia after treatment with intravenous acyclovir followed by oral valacyclovir. Arch Neurol 2006;63(7):940-2
   PubMedGoogle Scholar
• Acosta EP, Balfour HH Jr. Acyclovir for treatment of postherpetic neuralgia: efficacy and pharmacokinetics. Antimicrob Agents Chemother 2001;45(10):2771-4
   PubMedGoogle Scholar
• He L, Zhang D, Zhou M, Zhu C. Corticosteroids for preventing postherpetic neuralgia. Cochrane Database Syst Rev 2008;(1):CD005582
   Google Scholar
• British national formulary: London : British Medical Association : Pharmaceutical Society of Great Britain
   Google Scholar
• van Wijck AJ, Opstelten W, Moons KG, et al. The PINE study of epidural steroids and local anaesthetics to prevent postherpetic neuralgia: a randomised controlled trial. Lancet 2006;367(9506):219-24
   PubMed Web of Science ®Google Scholar
• Pasqualucci A, Pasqualucci V, Galla F, et al. Prevention of post-herpetic neuralgia: acyclovir and prednisolone versus epidural local anesthetic and methylprednisolone. Acta Anaesthesiol Scand 2000;44(8):910-8
   PubMed Web of Science ®Google Scholar
• Kotani N, Kushikata T, Hashimoto H, et al. Intrathecal methylprednisolone for intractable postherpetic neuralgia. N Engl J Med 2000;343(21):1514-9
   PubMed Web of Science ®Google Scholar
• Uscategui T, Doree C, Chamberlain IJ, Burton MJ. Corticosteroids as adjuvant to antiviral treatment in Ramsay Hunt syndrome (herpes zoster oticus with facial palsy) in adults. Cochrane Database Syst Rev 2008;(3):CD006852
   Google Scholar
• Sullivan FM, Swan IR, Donnan PT, et al. Early treatment with prednisolone or acyclovir in Bell's palsy. N Engl J Med 2007;357(16):1598-607
   PubMed Web of Science ®Google Scholar
• Hempenstall K, Nurmikko TJ, Johnson RW, et al. Analgesic therapy in postherpetic neuralgia: a quantitative systematic review. PLoS Med 2005;2(7):e164
   PubMed Web of Science ®Google Scholar
• Gilron I, Bailey JM, Tu D, et al. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 2005;352(13):1324-34
   PubMed Web of Science ®Google Scholar
• Dworkin RH, O'Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007;132(3):237-51
   PubMed Web of Science ®Google Scholar
• Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev 2007;(4):CD005454
   Google Scholar
• Rose MA, Kam PC. Gabapentin: pharmacology and its use in pain management. Anaesthesia 2002;57(5):451-62
   PubMed Web of Science ®Google Scholar
• Rowbotham M, Harden N, Stacey B, et al. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 1998;280(21):1837-42
   PubMed Web of Science ®Google Scholar
• Rice AS, Maton S. Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. Pain 2001;94(2):215-24
   PubMed Web of Science ®Google Scholar
• Gore M, Sadosky A, Tai KS, Stacey B. A retrospective evaluation of the use of gabapentin and pregabalin in patients with postherpetic neuralgia in usual-care settings. Clin Ther 2007;29(8):1655-70
   PubMed Web of Science ®Google Scholar
• Jones DL, Sorkin LS. Systemic gabapentin and S(+)-3-isobutyl-gamma-aminobutyric acid block secondary hyperalgesia. Brain Res 1998;810(1-2):93-9
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Corbin AE, Young JP Jr, et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2003;60(8):1274-83
   PubMed Web of Science ®Google Scholar
• Sabatowski R, Galvez R, Cherry DA, et al. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. Pain 2004;109(1-2):26-35
   PubMed Web of Science ®Google Scholar
• Stacey BR, Barrett JA, Whalen E, et al. Pregabalin for Postherpetic Neuralgia: Placebo-Controlled Trial of fixed and flexible dosing regimens on Allodynia and time to onset of pain relief. J Pain 2008;9(11):1006-17
   PubMed Web of Science ®Google Scholar
• Kochar DK, Garg P, Bumb RA, et al. Divalproex sodium in the management of post-herpetic neuralgia: a randomized double-blind placebo-controlled study. QJM 2005;98(1):29-34
   PubMed Web of Science ®Google Scholar
• Eisenberg E, McNicol E, Carr DB. Opioids for neuropathic pain. Cochrane Database Syst Rev 2006;3:CD006146
   Google Scholar
• Watson CP, Babul N. Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology 1998;50(6):1837-41
   PubMed Web of Science ®Google Scholar
• Raja SN, Haythornthwaite JA, Pappagallo M, et al. Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2002;59(7):1015-21
   PubMed Web of Science ®Google Scholar
• Boureau F, Legallicier P, Kabir-Ahmadi M. Tramadol in post-herpetic neuralgia: a randomized, double-blind, placebo-controlled trial. Pain 2003;104(1-2):323-31
   PubMed Web of Science ®Google Scholar
• Khaliq W, Alam S, Puri N. Topical lidocaine for the treatment of postherpetic neuralgia. Cochrane Database Syst Rev 2007;(2):CD004846
   Google Scholar
• Lidocaine plasters for postherpetic neuralgia? Drug Ther Bull 2008;46(2):14-6
   PubMedGoogle Scholar
• Lin PL, Fan SZ, Huang CH, et al. Analgesic effect of lidocaine patch 5% in the treatment of acute herpes zoster: a double-blind and vehicle-controlled study. Reg Anesth Pain Med 2008;33(4):320-5
   PubMed Web of Science ®Google Scholar
• Mason L, Moore RA, Derry S, et al. Systematic review of topical capsaicin for the treatment of chronic pain. BMJ 2004;328(7446):991
   PubMed Web of Science ®Google Scholar
• Backonja M, Wallace MS, Blonsky ER, et al. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study. Lancet Neurol 2008;7(12):1106-12
   PubMed Web of Science ®Google Scholar
• Attal N, Ranoux D, Morain F, Bouhassira D. Botulinum Toxin A Induces Direct Analgesic Effects on neuropathic pain: A Randomised Placebo Controlled Study. 12th World Congress on Pain. Glasgow 2008
   Google Scholar
• Guris D, Jumaan AO, Mascola L, et al. Changing varicella epidemiology in active surveillance sites–United States, 1995-2005. J Infect Dis 2008;197(Suppl 2):S71-5
   PubMed Web of Science ®Google Scholar
• Lopez AS, Kolasa MS, Seward JF. Status of school entry requirements for varicella vaccination and vaccination coverage 11 years after implementation of the varicella vaccination program. J Infect Dis 2008;197(Suppl 2):S76-81
   Google Scholar
• Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005;352(22):2271-84
   PubMed Web of Science ®Google Scholar